D. Saffran

发表

Alternative signals to RAS for hematopoietic transformation by the BCR-ABL oncogene

O. Witte, A. Goga, Jami McLaughlin, 1995, Cell.

Mutation of unique region of Bruton's tyrosine kinase in immunodeficient XID mice.

D J Rawlings, L Cohen, D. Largaespada, 1993, Science.

Structure-Based Design of Potent and Selective CK1γ Inhibitors.

H. Bregman, J. Newcomb, Xin Huang, 2012, ACS medicinal chemistry letters.

Anti-PSCA mAbs inhibit tumor growth and metastasis formation and prolong the survival of mice bearing human prostate cancer xenografts

R. Hubert, O. Witte, A. Raitano, 2001, Proceedings of the National Academy of Sciences of the United States of America.

Target Antigens for Prostate Cancer Immunotherapy

O. Witte, R. Reiter, D. Saffran, 2004, Cancer and Metastasis Reviews.

Cancer Epithelia Protease Results in Its Secretion by Prostate and Prostate Catalytic Cleavage of the Androgen-regulated TMPRSS 2 Updated Version

R. Hubert, I. Vivanco, A. Raitano, 2001 .

Deletion within the Src homology domain 3 of Bruton's tyrosine kinase resulting in X-linked agammaglobulinemia (XLA)

M. Vihinen, H. Ochs, O. Witte, 1994, Journal of Experimental Medicine.

Identification of a human bone marrow-derived immunoenhancing factor, BDEF.

D. Saffran, F. Mortari, S. K. Singhal, 1989, Cellular immunology.

Development of novel dual binders as potent, selective, and orally bioavailable tankyrase inhibitors.

H. Bregman, J. Newcomb, P. Andrews, 2013, Journal of medicinal chemistry.

Development of btk transgenic mice.

O. Witte, D. Rawlings, D. Saffran, 1995, Current topics in microbiology and immunology.

The immunoregulatory role of bone marrow. IV. Role of an immunoenhancing glycoprotein derived from murine bone marrow.

D. Saffran, S. K. Singhal, S. Puchalski, 1986, Cellular immunology.

Establishment of a reproducible culture technique for the selective growth of B-cell progenitors.

O. Witte, D. Saffran, E. Faust, 1992, Current topics in microbiology and immunology.

Further characterization of murine bone marrow-derived natural suppressor cells. Potential relationships between NS and NK/LAK activities.

D. Saffran, S. K. Singhal, 1990, Cellular immunology.

Structure-based design of 2-aminopyridine oxazolidinones as potent and selective tankyrase inhibitors.

Steve Schneider, Xin Huang, Angel Guzman-Perez, 2013, ACS medicinal chemistry letters.

Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia

Ornella Parolini, Mary Ellen Conley, Satoshi Tsukada, 1993, Cell.

Immunotherapy of established tumors in mice by intratumoral injection of interleukin-2 plasmid DNA: induction of CD8+ T-cell immunity.

K. Barnhart, H. Horton, P. Hobart, 1998, Cancer gene therapy.

AMG 900, a Small-Molecule Inhibitor of Aurora Kinases, Potentiates the Activity of Microtubule-Targeting Agents in Human Metastatic Breast Cancer Models

T. Bush, R. Loberg, Grace Chung, 2013, Molecular Cancer Therapeutics.

Catalytic cleavage of the androgen-regulated TMPRSS2 protease results in its secretion by prostate and prostate cancer epithelia.

R. Hubert, E. Chen, I. Vivanco, 2001, Cancer research.

STEAP: a prostate-specific cell-surface antigen highly expressed in human prostate tumors.

R. Hubert, I. Vivanco, A. Raitano, 1999, Proceedings of the National Academy of Sciences of the United States of America.

Impact of Hydrolysis-Mediated Clearance on the Pharmacokinetics of Novel Anaplastic Lymphoma Kinase Inhibitors

L. Berry, Y. Teffera, Jingzhou Liu, 2013, Drug Metabolism and Disposition.

The discovery and optimization of a novel class of potent, selective, and orally bioavailable anaplastic lymphoma kinase (ALK) inhibitors with potential utility for the treatment of cancer.

Karina Romero, Renee Emkey, Hao Chen, 2012, Journal of medicinal chemistry.

Regulation of B-cell differentiation by stromal cells

O. Witte, D. Saffran, E. Faust, 1995 .

Brief report: a point mutation in the SH2 domain of Bruton's tyrosine kinase in atypical X-linked agammaglobulinemia.

O. Witte, D. Rawlings, O. Parolini, 1994, The New England journal of medicine.

The molecular pathogenesis of XLA involves a spectrum of mutations in Bruton's tyrosine kinase

O. Witte, D. Saffran, 1994 .

Antitumor activity of motesanib alone and in combination with cisplatin or docetaxel in multiple human non–small-cell lung cancer xenograft models

A. Coxon, A. Polverino, S. Kaufman, 2012, Molecular Cancer.

Broad Antitumor Activity in Breast Cancer Xenografts by Motesanib, a Highly Selective, Oral Inhibitor of Vascular Endothelial Growth Factor, Platelet-Derived Growth Factor, and Kit Receptors

Paul Hughes, Richard Kendall, T. Bush, 2009, Clinical Cancer Research.

BroadAntitumorActivity inBreastCancerXenograftsbyMotesanib , aHighly Selective , Oral Inhibitorof Vascular Endothelial Growth Factor , Platelet-DerivedGrowth Factor , andKit Receptors

T. Bush, K. Rex, A. Coxon, 2008 .

Modulating Androgen Receptor-Driven Transcription in Prostate Cancer with Selective CDK9 Inhibitors.

Charles Y. Lin, S. Knapp, T. Westbrook, 2020, Cell chemical biology.

Distinctive growth requirements and gene expression patterns distinguish progenitor B cells from pre-B cells

O. Witte, D. Williams, D. Toksoz, 1993, The Journal of experimental medicine.

Antitumor activity of motesanib alone and in combination with cisplatin or docetaxel in multiple human non–small-cell lung cancer xenograft models

A. Coxon, A. Polverino, Man Xu, 2012, Molecular Cancer.

Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia. 1993.

T. Mohandas, J. Belmont, O. Witte, 2012, Journal of immunology.

Cell-mediated cytotoxicity results from, but may not be critical for, primary allograft rejection.

S. Ju, F. Hayashi, D. Saffran, 1996, Journal of Immunology.

Abstract 1795: Characterization of a novel series of potent, selective inhibitors of wild type and mutant/fusion anaplastic lymphoma kinase

D. Whittington, P. Andrews, K. Wilcoxen, 2012 .